GlaxoSmithKline CEO Andrew Witty has said moving the European Medicines Agency (EMA) from London will cause “tremendous disruption.”
Witty is worried moving the EMA and its 900 staff from London to another European city post-Brexit will cause upheaval that affects the smooth running of the regulatory machinery.
The fate of EMA is one of many questions raised by the United Kingdom’s vote to leave the European Union. Politicians across Europe are lobbying for EMA to move to their country once the U.K. leaves the EU. And, faced with threats that foreign biopharma investment will fall if EMA leaves London, the U.K. is also pushing to retain the headquarters of the regulator even as it plans to sever its links to the EU.
Witty, like other pharma execs with major U.K. operations, wants EMA to stay in London. To make the case, Witty has branched out beyond the links between EMA and the U.K. regulator that others have played up. The CEO chose instead to focus on the best outcome for patients, which also happens to be his preferred result from a business perspective.
“A lot of staff are going to have to change positions,” Witty told Bloomberg Television. “Those who don’t leave have to relocate. This is a regulator who is keeping an eye on the health and safety of hundreds of millions of Europeans. You don’t want them with their eye off the ball.”
There is evidence the uncertainty created by Brexit is already affecting EMA. Talking to European politicians earlier this month, EMA Executive Director Guido Rasi said good candidates for jobs at the agency are withdrawing their applications, Regulatory Focus reports. Six employees resigned in the month following the Brexit vote. Rasi wants additional measures to support staff.
The uncertainty is likely to continue for some time. When asked about how the U.K. will handle drug approvals and other regulatory tasks post-Brexit, the politicians in charge of managing the process have given a range of noncommittal answers.
Some government politicians have proposed a Norway-style relationship that keeps the U.K. in the EU regulatory network. Others have shown a willingness to make a clean split. A middle-ground that sees the U.K. standardize its approval process with the EU in an attempt to avoid becoming a lower-priority market for drugmakers is also on the cards.
By Nick Paul Taylor
Source: Fierce Biotech
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
